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Abstract
Directly observed therapy (DOT) is almost universally used for the treatment of TB. Several
meta-analyses using different methods have assessed the effectiveness of DOT compared
to self-administered therapy (SAT). The results of these meta-analyses often conflict with
some concluding DOT is superior and others that there is little or no difference. Meta-analy-
ses can guide policymaking, but such analyses must be reliable. To assess the validity of a
previous meta-analysis, we tried to reproduce it. We encountered problems with the previ-
ous analysis that did not allow for a meaningful reproduction. We describe the issues we
encountered here. We then performed a new meta-analysis comparing the treatment out-
comes of adults given treatment with SAT versus DOT. Outcomes in the new analysis are
loss to follow-up, treatment failure, cure, treatment completed, and all-cause mortality. All
data, documentation, and code used to generate our results is provided. Our new analysis
included four randomized and three observational studies with 1603 and 1626 individuals
respectively. The pooled relative risks (RR) are as follows: Lost to follow-up (RR = 1.2, 95%
CI 0.9, 1.7), Treatment Failure (RR = 1.1, 95% CI 0.6, 2), Cure (RR = 0.9, 95% CI 0.8, 1.1),
Treatment Completion (RR = 1, 95% CI 0.9, 1.1), Mortality (RR = 0.9, 95% CI 0.6, 1.3).
Based on data from our new meta-analysis, the magnitude of the difference between DOT
and SAT for all reported outcomes is small, and none of the differences are statistically
significant.
Introduction
Directly observed therapy (DOT) for the treatment of tuberculosis (TB) is a component of the
World Health Organization’s (WHO) recommended DOTS program. While the DOTS pro-
gram has been successful in reducing tuberculosis incidence, the average annual decrease is far
short of the needed reduction to meet the goals of the WHO End TB strategy [1]. DOT
requires patients with TB to be observed by another individual while taking their medicine.
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Evidence to support DOT’s effect on cure rates [2,3], adherence [2,3], or any other measure of
treatment success is not very compelling [4,5]. Leading to an intense debate about the use and
effectiveness of DOT [6–9].
A meta-analysis of data from six randomized controlled trials (RCT) suggested that DOT
did not increase the cure or treatment completion significantly [3]. We believe that due to the
small number of RCT and the high likelihood that there will not be any new ones addressing
this issue, it is necessary also to consider the evidence from observational studies. Tian and
others reported the findings from eight RCTs and fifteen observational studies [10]. They
found DOT to be more successful than SAT when the analysis was restricted to observational
studies, but no difference was observed among RCT. Their analysis included retrospective
cohort and cross-sectional studies, which are generally considered to provide lower quality evi-
dence. To ensure the best quality evidence, we believe only prospective studies should be con-
sidered [11].
One previous meta-analysis included both RCT and prospective cohort studies (PCS) [12].
This study by Pasipanodya and Gumbo (which will be referred to as PG), included five RCT
and five PCS. The inclusion of prospective studies helps provide valuable information without
the high risk of bias associated with retrospective studies. However, PG’s study was criticized
due to methodological concerns [13–15]. Thus, calls to gather more evidence to define the
effectiveness of DOT versus SAT are still being made [8].
Since the question of DOT vs. SAT is a significant public health issue, we deemed it valuable
to try and reproduce the results found by PG, taking into account and addressing previously
raised criticisms as needed. In doing so, our investigation found other inconsistencies in PG
beyond those already raised [13–15]. This prevented us from reproducing the results presented
in PG. We instead performed an entirely new analysis that is reproducible and based on what
we consider to be the most appropriate data and analysis methodology. Our analysis confirms
results for RCT studies that there is little evidence for the superiority of DOT versus SAT in
regards to any of the WHO-defined treatment outcomes.
Methods
Standards
We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) guidelines [16].
Search strategy
We performed a systematic search of the literature from January 1st, 1960 to July 7th, 2016.
The search included Pub Med and gray literature such as The Cochrane library. The studies
found were reviewed and assessed by two researchers independently for inclusion (BM and
MC), and consensus resolved any conflict. We attempted to contact authors if the published
data were not complete or were reported in a manner that results in the desired population
were not available. Further details can be found in the supplementary material (SM).
Study selection criteria
Included studies met the following criteria: patients were diagnosed by microscopic examina-
tion of sputum smear or culture, assigned to either DOT or SAT, evaluated for treatment fail-
ure during the treatment, and were treated with short-course chemotherapy regimen
including isoniazid, rifampin, and pyrazinamide. Study designs were limited to RCT and PCS.
Studies were excluded based on the following criteria: study population includes children
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(< 15 years), retrospective design, included specialized re-treatment regimens or biased
assignment of patients receiving re-treatment. Studies were not excluded based on the lan-
guage unless reasonable attempts to have them translated failed.
Exposure definitions
We used DOT definitions created by the WHO, which defines DOT as “an element of the
DOTS program and refers to the direct observation of patients swallowing their medication”
[17]. The observers in some studies are family members, community members or lay medical
personnel. The training level of these individuals is not always clear, but studies have shown
the impact of training level on outcomes is negligible [2,18–21]. When a patient’s treatment
involves little or no supervision, it is considered SAT.
Outcomes
Outcomes are defined by the WHO [17]. Included in the final analysis are lost to follow-up
(LTFU), treatment failure, treatment completion, death, and cure. Lost to follow-up is used in
place of the term “default” and is defined as an individual that does not complete treatment.
Data abstraction and quality assessment of included studies
Data were abstracted independently by two researchers (BM and MC), and any disagreements
were settled by consensus. We contacted the authors of studies that include children, retreat-
ment, or extrapulmonary TB in an attempt to get the data excluding these individuals. Simi-
larly, the authors of papers that only report some of the treatment outcomes or do not report
the data in a usable format were also contacted.
To assess study quality, we used the “Cochrane Risk of Bias Tool for Cohort Studies”
(CRBCS) to evaluate bias and quality of the PCS [22], and the Jadad score for RCT [23]. Two
investigators (BM and MC) assessed study quality independently, and any disagreements were
resolved by consensus. We compared the results of our data re-abstraction, study selection,
and study quality to those obtained in PG. A detailed examination of differences in study
inclusion between PG and our analysis is included in the SM.
Data analysis
All analyses were done in R [24] using the “metafor” package [25]. Relative risk (RR) was used
as the primary outcome. RR is preferred over risk difference (RD) because RR accounts for the
baseline risk and provides a more consistent summary of effects [26].
Relative risk was calculated as SAT risk over DOT risk. A RR less than 1 for a positive out-
come or a RR greater than 1 for an adverse outcome indicates that DOT is favored.
Since some of the studies had no events for outcomes, we used a continuity correction of
adding .5 to all the cells in any 2x2 table with a single 0. We did not exclude studies with zero
outcomes from the RR analysis [27]. PG reported effect size using the DerSimonian Laird
(DL) method. In a meta-analysis of only a few studies, with each study having a diverse sample
and effect size, the DL method can lead to biased estimates of overall effect and underestimate
the amount of heterogeneity [28–31]. We believe the use of restricted maximum likely hood is
more appropriate and used it for all the random effects models [28,32].
To decide on the statistical model to use, PG used fixed effects if I2 < 30% and random
effects if I2 > 30%. While this approach is common, we contend that it is not entirely appropri-
ate. Instead, the model choice should be determined based on the assumptions about the
underlying biology and distribution of the included studies [33]. Since the studies will likely be
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from different settings with different populations, there is no reason to assume a priori that
effect sizes should be the same. Therefore, a random effects model is more appropriate irre-
spective of the amount of heterogeneity, and it was used for all effect size calculations [33].
PG performed a meta-regression to investigate and explain the observed heterogeneity
between studies. We decided that due to the small sample size it was not appropriate. Instead,
we examined the effects of study design via subgroup analysis. As done by PG, publication bias
is assessed using visual inspection and the Egger test of funnel plot symmetry [34]. Since the
overall sample of studies is small, these tests may lack sufficient power. We therefore also
included Orwin’s method of “N Fail Safe” and the “Trim and Fill” methods to provide addi-
tional information when judging publication bias [35].
We also performed a systematic sensitivity analysis to identify studies that may be outliers
and studies with a significant level of influence on the estimated effect size.
Results
Reproducibility of PG
Study selection. Our set of studies included four RCTs and two PCSs. These studies dif-
fered from studies reported in PG: one RCT [36] and 4 PCS [37–40] included in PG should
not have been included by PG based on their stated exclusion and inclusion criteria. We found
two additional observational studies that met the inclusion criteria [41,42] which were not
included in PG. With the information provided by PG, it is not possible to tell whether the
studies were not found by PG or if they were included in the search results but not included in
the analysis. Further details are provided in the SM.
Quality assessment of studies. We re-evaluated the quality of all the included studies
from PG with the Jadad score for comparison. Assessing the quality of the RCT, we found a
low risk of bias and overall high quality for three RCT which agreed with PG. There was dis-
agreement for one RCT that we found to have a high risk of bias [36]. Assessing the quality of
PCS with the Jadad score, we did not agree with PG that there was a low risk of bias. Using the
Jadad score all of the PCS are given a score of 1, but when re-evaluated with the CRBCS all but
one of the studies was shown to be of good quality. Further details are provided in the SM.
Treatment outcomes. We were unable to reproduce PG’s results for lost to follow-up (Fig
1 and Table 2 in [12]), even when we tried to use the same underlying studies, data, and meth-
ods. We provide detailed information on our inability to reproduce those results (Figures P-R
and Tables Z-AA in SM). PG analyzed the outcomes of relapse and acquired drug resistance.
Since none of the studies which reported these outcomes meet the inclusion criteria (either
ours or those in PG), and since these studies were not designed to assess the differences
between DOT and SAT for these outcomes [13], we decided that those analyses were not
meaningful and did not try to perform them.
New meta-analysis of DOT vs. SAT
Study Selection and Characteristics. Our systematic review generated 166 unique results,
11 [39–49] studies compared DOT and SAT treatment outcomes in a prospective manner (Fig
1). We contacted the authors of 4 papers in an attempt to get the data on the population of
interest; specifically, data on adults only [39,40,42,48] and data stratified by new or re-treat-
ment patients [42] for certain outcomes. We received responses from authors of 2 studies, but
neither was able to provide the data. We received no response from the corresponding authors
of the other papers. In total 7 [41–44,46,47,49] studies met the inclusion criteria for at least one
of the outcomes of interest.
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The total number of individuals across all included studies is 3229. This number is less than
the 13751 individuals reported in PG due to erroneous inclusion of several additional studies,
as described above. Of those 3229 individuals, 1603 were randomized to interventions, 914to
DOT, and 689 to SAT. The remaining 1626 patients came from PCS and were not randomly
assigned to a treatment group, 998 received DOT, and 628 received SAT. A spreadsheet which
provides detailed information on the systematic search and data abstraction is provided in the
SM.
Quality assessment of included studies. Assessing the quality of the RCT [43,44,47,49],
we found a low risk of bias and overall high quality. Assessing the quality of the PCS, we found
one study to be of high quality with a low risk of bias [46]. The other two studies were found to
be at an increased risk of bias [41,42]. A spreadsheet detailing the quality assessment of all the
studies is included in the SM.
Lost to follow-up. The pooled risk of LTFU in the SAT group was 19.7% (95% CI 10.2,
29.1) vs. 16.1% (95% CI 6.5, 25.7) for the DOT group (Fig 2). The calculated risks for individ-
ual studies are shown in the supplementary materials (Table A in S1 Text). The pooled RR was
1.2 (95% CI 0.9, 1.7). The pooled RD (RD = SAT—DOT) was 3.7% (95% CI -1.2, 8.7).
Figure for the RD is in the SM (Figure A in S1 Text). Both measures indicate that DOT is
favored in reducing the risk of LTFU, but the results are not statistically significant. This result
disagrees with the significant difference favoring DOT reported in PG [12].
Treatment failure. The pooled risk of treatment failure in the SAT group was 2.1% (95%
CI 0.3, 3.8) and 1.3 (95% CI 0.4, 2.1) for the DOT group (Fig 3). The calculated risks for indi-
vidual studies are shown in the supplementary materials (Table B in S1 Text). The pooled RR
was 1.1 (95% CI 0.6, 2). The pooled RD was 0.5% (95% CI -1, 1.9). Figure for the RD is in the
SM (Figure B in S1 Text). Both measures indicate that DOT is slightly favored over SAT, but
the results are not statistically significant.
Completion of treatment. The pooled risk of completing treatment in the SAT group
was 71.5% (95% CI 65, 78) vs. 72.3% (95% CI 63.4, 81.2) for the DOT group (Fig 4). The
Fig 1. PRISMA diagram. Results of systematic literature review.
https://doi.org/10.1371/journal.pone.0217219.g001
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calculated risks for individual studies are shown in the supplementary materials (Table C in S1
Text). The pooled RR was 1 (95% CI 0.9, 1.1). The pooled RD was -2.1% (95% CI -8, 3.9).
Figure for the RD is in the SM (Figure C in S1 Text). Both measures show no evidence of any
difference between DOT and SAT.
Death. The pooled risk of death in the SAT group was 3.1% (95% CI 1.6, 4.6) vs. 3.2%
(95% CI 1.6, 4.7) for the DOT group (Fig 5). The calculated risks for individual studies are
shown in the supplementary materials (Table D in S1 Text). The pooled RR was 0.9 (95% CI
0.6, 1.3). The pooled RD was -0.1% (95% CI -2.1, 1.9). Figure for the RD is in the SM (Figure D
in S1 Text). The overall RR indicates that SAT is slightly favored over DOT, but the results are
not statistically significant or consistent between study design type.
Cure. The pooled risk of cure in the SAT group was 56.7% (95% CI 47.6, 65.8) vs. 59.1%
(95% CI 43, 75.1) for the DOT group (Fig 6). The calculated risks for individual studies are
shown in the supplementary materials (Table E in S1 Text). The pooled RR was 0.9 (95% CI
0.8, 1.1). The pooled RD was -4% (95% CI -13.1, 5.1). Figure for the RD is in the SM (Figure E
in S1 Text). Both measures indicate that DOT is slightly favored over SAT, but the results are
not statistically significant.
Sensitivity and influence. Lost to follow-up was the only outcome that was sensitive to
the absence of a single study [46]. When the study is removed, the point estimated risk differ-
ence becomes statistically significant, and the estimated heterogeneity goes to zero. Detailed
results of the sensitivity and influence analysis for each outcome are included in the SM
(Table F-Y in S1 Text).
Publication bias. None of the statistical tests or visual inspection of the funnel plots indi-
cated the presence of publication bias for any of the included outcomes. It is important to note
that the power to detect any publication bias is small with so few studies. Detailed results are
shown in the SM (Figure F-O in S1 Text).
Fig 2. LTFU relative risk stratified by study design. Q = Cochrane’s Q; df = Degrees of Freedom; p = P-value
associated with Q; I2 = Proportion of variation due to heterogeneity and corresponding 95% confidence interval.
https://doi.org/10.1371/journal.pone.0217219.g002
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Discussion
History has demonstrated that TB control is required to protect public health [50], but the
DOT component of TB control has been more controversial. There are a number of meta-
Fig 3. Treatment failure relative risk stratified by study design. Q = Cochrane’s Q; df = Degrees of Freedom; p = P-
value associated with Q; I2 = Proportion of variation due to heterogeneity and corresponding 95% confidence interval.
https://doi.org/10.1371/journal.pone.0217219.g003
Fig 4. Completion of treatment relative risk stratified by study design. Q = Cochrane’s Q; df = Degrees of Freedom;
p = P-value associated with Q; I2 = Proportion of variation due to heterogeneity and corresponding 95% confidence
interval.
https://doi.org/10.1371/journal.pone.0217219.g004
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analyses that have been published, and the methodology used for the systematic search of the
literature appears to impact the results. Specifically, the types of study designs included seems
to determine if the findings are statistically significant or not. Studies that include retrospective
studies favor DOT and show a statistically significant difference when comparing DOT and
SAT [10,51,52].
Additionally, the definition for DOT and SAT groups can vary significantly within and
between meta-analyses. This leads to differences in the studies included as well as how study
groups are divided. These issues confirm the need for transparent and complete reporting of
the methods used to generate the results for a meta-analysis. Recent Cochrane meta-analyses
addressed the effectiveness of DOT, but only included RCT and concluded that there is little
evidence in favor of DOT [2,3]. Due to the small number of RCT and the high likelihood that
there will not be any new ones addressing this issue, it is useful to include data from PCS to
provide a more comprehensive assessment of treatment outcomes for DOT and SAT. While
the inclusion of PCS is controversial, it provides additional information and is useful when
only a few RCT are available.
A previous meta-analysis by PG included both RCT and PCS. However, as described here,
their analysis had methodologic issues rendering their results unreliable [13–15]. Our new
meta-analysis corrects problems found in PG and expands the scope of the Cochrane review
by including not only RCT but also PCS. We have attempted to make our study easy to repro-
duce. To that end, all the data and code required to reproduce all our results, as well as, docu-
mentation of the entire systematic review process, are provided in the SM. In contrast to PG,
we did not find a statistically significant difference between DOT and SAT as regards to LTFU.
Similar to past Cochrane reviews[2,3] and PG, we found no statistically significant difference
between DOT and SAT for treatment failure. Our findings are in agreement with meta-analy-
ses including only RCT [2,3]. Despite the inclusion of both RCT and PCS, the amount of data
available for analysis is still limited, which constrains the power of the results and leads to at
Fig 5. Death relative risk stratified by study design. Q = Cochrane’s Q; df = Degrees of Freedom; p = P-value
associated with Q; I2 = Proportion of variation due to heterogeneity and corresponding 95% confidence interval.
https://doi.org/10.1371/journal.pone.0217219.g005
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times wide confidence intervals. Attempts to obtain additional data from published studies
were unsuccessful. The inclusion of these data could change the results of our analysis.
We did not address the effects of DOT on the development of secondary drug resistance
because of the paucity of the information. The emergence of multi-drug resistant TB and
extensively drug-resistant TB threatens TB control now and in the future. In theory, direct
observation of effective medications may reduce the likelihood of acquired drug resistance.
Evaluating acquired drug resistance as the primary outcome in a meta-analysis may require
greater dependence on observational data, since extensive clinical trials may not be feasible.
The results of our study suggest that in adult patients with smear or culture-positive tuber-
culosis, there is little evidence that DOT is better than SAT. While there often seems to be
some indication that DOT is better than SAT, the observed difference is small. Our analysis
found no statistically significant differences between DOT and SAT for the primary indicators
of treatment success when considering both RCT and PCS. Only in the stratified analysis of
RCT studies is there any evidence of a significant difference between DOT and SAT for the
RD of LTFU. We believe our findings further support the current lack of evidence that DOT is
superior to SAT for improving cure rates, adherence [2,3], or any other measure of treatment
success [4,5]. It is important to note that despite the importance of TB we agree there is a lack
of high-quality data available in the literature [8], and while we believe traditional RCTs are
unlikely to occur in the future there is a need for more high-quality evidence in the form of
prospective cohort and cluster randomized trials [8]. Such studies could provide a clear under-
standing of the effectiveness of DOT. Additionally, the ability to compare novel means of treat-
ment monitoring should be conducted based on the needs and consideration of the
populations being served[53].
In summary, we could not reproduce a previous meta-analysis, due to inconsistencies
regarding study inclusion and insufficient information about the analysis methods. Further
improvements toward robust reproducibility of meta-analyses, especially those directly related
to interventions are needed [54–57]. Our new analysis found that for adult patients 15 years or
Fig 6. Cure relative risk stratified by study design. Q = Cochrane’s Q; df = Degrees of Freedom; p = P-value
associated with Q; I2 = Proportion of variation due to heterogeneity and corresponding 95% confidence interval.
https://doi.org/10.1371/journal.pone.0217219.g006
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older with drug-susceptible pulmonary TB, there is no statistically significant difference
between DOT and SAT and the magnitude of the difference between DOT and SAT for all
reported outcomes is small. The role of DOT in the DOTS strategy remains controversial and
we agree with McLaren et al. that further efforts are needed to evaluate its role [8].
Data sharing statement
Documentation and data for reproducibility are freely available in the supplementary
materials.
Supporting information
S1 Text. Supplementary Documentation. This document contains information about all the
supplementary materials, explains how to reproduce the results of our analysis, and has addi-
tional results not shown in the main text.
(DOCX)
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